drugset / Trial / NCT00992121
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
RandomizedSingle-groupOpen-labelOther
Summary
This study will determine whether blood tests, tumour imaging and tumour tissue analysis can reveal effects of drugs that block blood vessel growth (angiogenesis) in patients with renal cancer.
Timeline
- Start
- 2009-11-18
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Pazopanib | Small molecule | 200 mg | Oral |
| Subject | Pazopanib | Small molecule | 400 mg | Oral |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Subject | Pazopanib | Small molecule | 1200 mg | Oral |